This article is more than 5 years old. Information may no longer be current.

Patients with advanced pancreatic NET achieved 44-month OS with Afinitor

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Results from a phase 3 trial presented at the European Society for Medical Oncology 2014 Congress in Madrid showed overall survival of more than 3.5 years in patients with advanced and progressive pancreatic neuroendocrine tumors treated with everolimus, according to a press release.

“The median overall survival of 44 months for everolimus (Afinitor, Novartis) is unprecedented in controlled clinical trials for advanced progressive pancreatic neuroendocrine tumors (pNET),” James Yao, MD, University of Texas MD Anderson Cancer Center, said in the release. “The results affirm the importance of targeting key pathways involved in tumor growth, such as the mTOR [mammalian target of rapamycin] pathway in advanced pNET.”

According to the release, participants in the RADIANT-3 trial had well-differentiated advanced and progressive pNET and received everolimus tablets plus best supportive care or placebo plus best supportive care. Median overall survival (OS) was 44.02 months (95% CI, 35.61-51.75) with everolimus compared with 37.68 months (95% CI, 29.14-45.77) with placebo. While the difference did not reach statistical significance (HR=0.94; 95% CI, 0.73-1.2), an 85% crossover of patients from placebo to everolimus “likely contributed to the long median OS in the placebo arm … and may have confounded the ability to detect a difference in the OS results,” the release said. The safety profile was consistent with past observations; the most common adverse events included stomatitis, rash, diarrhea and fatigue.

The results will be submitted to health authorities for inclusion in Afinitor prescribing information, the release said.

For more information:

Oberg K. Abstract #1132O. Presented at: European Society for Medical Oncology 2014 Congress; Sept. 26-30; Madrid, Spain.

Disclosure: See the abstract for a full list of relevant financial disclosures.